Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) announced a research collaboration and license agreement with Roche (OTC: RHHBY) in cancer immunotherapy (CIT) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE